CCR2 and pulmonary fibrosis: ECL1i has been functionalized with DOTA chelator to obtain radiolabeled probes for PET imaging in humans with pulmonary fibrosis (Brody et al. 2021), cardiovascular diseases [NCT05107596, NCT04592991, NCT04537403], head and neck cancer [NCT04217057] and for predicting response to CCR2-Targeted therapy in pancreatic cancer [NCT03851237].